CULLINAN THERAPEUTICS INC (CGEM) Stock News

NASDAQ:CGEM - Nasdaq - US2300311063 - Common Stock - Currency: USD

8.33 +0.22 (+2.71%)

After market: 8.33 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CGEM Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Taiho Oncology

Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

2 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

2 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

2 months ago - By: Taiho Oncology

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

2 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

2 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

2 months ago - By: Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

2 months ago - By: Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

3 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

3 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

3 months ago - By: Zacks Investment Research

Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know

3 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States

3 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

3 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

3 months ago - By: Benzinga - Mentions: AAPL FFIN NVDA HTZ ...

Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

3 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

3 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

3 months ago - By: Benzinga - Mentions: CYTK FLWS IRS LTM ...

Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

5 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

5 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

5 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

6 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

6 months ago - By: Taiho Oncology

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

8 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

8 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

9 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

9 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

9 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

9 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

9 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

9 months ago - By: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024